3 billion injections! Hesco has commented on the rush of stone medicine, Howson and so on

Pharma.com January 28 - January 27, the official website of the State Drug Administration shows that Liaoning Haisco Pharmaceutical injection with Esomeprazole sodium to supplement the application was approved.
, Jiangsu Zhengda Fenghai Pharmaceutical's injection of Esomerazo sodium was also approved for supplementary applications.
2019, sales of injections at the end of China's public medical institutions exceeded 3 billion yuan, according to the Company's internal network data.
, the injection of Esomerazole sodium has been Positive Day Qing Pharmaceutical Group, Jiangsu Osaikang Pharmaceuticals and other 7 enterprises have been evaluated.
January 27, 2021 Drug approval documents to be received information released in recent years, China's public medical institutions terminal Esomerazole (Esso meprazole) injection sales (units: 100 million yuan) Source: China's public medical institutions terminal competition pattern Mi net data show that 2019 Sales of Esomerazole (Esso meprazole) injections at the end of China's urban public hospitals, county-level public hospitals, urban community centers and township hospitals (China's public medical institutions) exceeded the 3 billion yuan mark, with AstraZeneone's market share the largest falling by 1.56% year-on-year in the first half of 2020.
market share has fallen rapidly in recent years as domestic pharmaceutical companies have gained strength, falling below 50% from its dominant market in 2015 to the first half of 2020.
Source: MED2.0 China Drug Review Database Up to now, 7 enterprises have been evaluated for injection of Esomeladium sodium, of which, Zhengda Tianqing Pharmaceutical Group, Jiangsu Osaikang Pharmaceuticals, Langtian Pharmaceuticals, Jiangsu Zhengda Fenghai Pharmaceuticals, Liaoning Haisco Pharmaceuticals were approved for supplementary applications, Chongqing Lemei Pharmaceuticals, Hunan Seron Pharmaceuticals with imitation 4 categories of declaration approved, as reviewed.
In addition, the product has Hunan Yige Pharmaceuticals, Shanghai Huilun Jiangsu Pharmaceuticals, Fu'an Pharmaceutical Group Hubei People's Pharmaceuticals and other 10 enterprises in the consistent evaluation of supplementary applications in the review and approval (in the drug review center), Shi Pharmaceutical Group Ohyi Pharmaceuticals, Jiangsu Howson Pharmaceuticals, Hainan Pelte Pharmaceuticals and other 7 enterprises to copy 4 categories of declarations listed in the review and approval (in the drug review center), after approval will be treated as the same.
source: official website of the State Drug Administration, Mi Net database